Epigenetics in cardiovascular health and disease

Prog Mol Biol Transl Sci. 2023:197:105-134. doi: 10.1016/bs.pmbts.2023.01.002. Epub 2023 Feb 8.

Abstract

Conrad Waddington's epigenetics landscape has provided a metaphorical framework for how cells progress from undifferentiated states to one of several discrete, distinct, differentiated cell fates. The understanding of epigenetics has evolved over time, with DNA methylation being the most studied epigenetic modification, followed by histone modifications and non-coding RNA. Cardiovascular diseases (CVD) are leading contributors to death worldwide, with the prevalence of CVDs increasing across the last couple of decades. Significant amount of resources being poured into researching key mechanisms and underpinnings of the various CVDs. These molecular studies looked at the genetics, epigenetics as well as the transcriptomics of various cardiovascular conditions, aiming to provide mechanistic insights. It has paved the way for therapeutics to be developed and in recent years, epi-drugs for the treatment of CVDs. This chapter aims to cover the various roles of epigenetics in the context of cardiovascular health and disease. The following will be examined in detail: the developments in basic experimental techniques used to study epigenetics, the role of epigenetics in various CVDs (hypertension, atrial fibrillation, atherosclerosis, and heart failure), and current advances in epi-therapeutics, providing a holistic view of the current concerted efforts in advancing the field of epigenetics in CVDs.

Keywords: Cardiovascular diseases; Epigenetics; Health; Molecular biology.

MeSH terms

  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular System* / metabolism
  • DNA Methylation
  • Epigenesis, Genetic
  • Humans
  • Protein Processing, Post-Translational